Stemline Therapeutics, Inc. (NASDAQ:STML) Q4 2019 Earnings Conference Call - Final Transcript
Mar 16, 2020 • 08:00 am ET
Good day, and welcome to the Stemline Earnings Conference Call. [Operator Instructions]
At this time, I would like to turn the conference over to Ken Hoberman. Sir, please go ahead.
Good morning, and thank you for joining us during these trying circumstances. Welcome to today's conference call to discuss our fourth quarter 2019 financial results. With me on today's call are members of management team including Ivan Bergstein, our Chief Executive Officer; David Gionco, our Chief Accounting Officer and Robert Francomano, our Chief Commercial Officer. After our prepared remarks, we will open the call to take your questions.
As a reminder, we may be making forward-looking statements. Our forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from our forecasts. A detailed description of these risks can be found in the forward-looking statements in Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2019 and in our quarterly report on Form 10-Q for the quarter ended September 30, 2019.
With that, I will now turn over the call to Ivan Bergstein, our CEO. Ivan, the floor is yours.
Thank you, Ken, and good morning, everyone. And I hope and trust everyone is doing their utmost to keep yourselves, your families, your friends, colleagues and communities as safe as possible in this unprecedented time of uncertainty. With these big issues facing us all, it almost seems trivial to have this call. But as P.T. Barnum was famous for saying, the show must go on.
And with that, let me distract us for a brief moment from a serious macro issues at hand to remind you that 2019 was a tremendous year for Stemline as we launched ELZONRIS, the first CD123 targeted agent ever approved. With ELZONRIS on the market and generating revenue, coupled with our strong balance sheet, we have built a strong foundation from which to grow as a company. This includes aggressively pursuing growth opportunities for ELZONRIS, both within and beyond BPDCN, including expanding the potential utility of ELZONRIS in additional CD123 positive indications. And we look forward to trial updates and data readouts in indications including CMML, chronic myelomonocytic leukemia; MF, myelofibrosis and AML, acute myeloid leukemia including in CD123 enriched population later this year and on into next year.
Ultimately, we see ELZONRIS as a potentially global product that has multiple approved indications, including a positive target phase label. And in parallel, we continue to advance our pipeline of additional agents, namely our novel and differentiated XPO1 inhibitor, SL-801 currently in Phase 1 trials of advanced solid tumor patients and our RET inhibitor, SL-1001 currently slotted to enter Phase 1 trial next year. Overall, we believe that with this multi-pronged approach and solid balance sheet, we are setting ourselves up for the potential for significant growth and success.
With that, I will now turn the call over to Robert Francomano, our Chief Commercial Officer, who will provide details on the